# In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

> **NCT06493799** · PHASE3 · RECRUITING · sponsor: **Green Cross Wellbeing** · enrollment: 226 (estimated)

## Conditions studied

- Chronic Liver Disease

## Interventions

- **DRUG:** LAENNEC (Human Placenta Hydrolysate) IV
- **DRUG:** LAENNEC (Human Placenta Hydrolysate) SC

## Key facts

- **NCT ID:** NCT06493799
- **Lead sponsor:** Green Cross Wellbeing
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06493799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06493799, "In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06493799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*